CG Oncology Accelerates PIVOT-006 Data Timeline to 1H 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Accelerated Data Release: CG Oncology announced that topline data from the PIVOT-006 clinical trial is now expected in the first half of 2026, nearly a year ahead of schedule, demonstrating the company's rapid progress in the intermediate-risk non-muscle invasive bladder cancer (NMIBC) space.
- Broad Participation: The trial has enrolled over 360 patients across more than 90 sites, highlighting the urgent need for new therapies in this area and laying the groundwork for the company's future market expansion.
- Market Potential: The intermediate-risk NMIBC patient population in the U.S. is estimated to exceed 50,000, and CG Oncology aims to broaden its market reach with this innovative therapy to address unmet medical needs.
- Innovative Treatment: Cretostimogene is a novel oncolytic immunotherapy, with ongoing clinical development including two Phase 3 trials, showcasing the company's strategic positioning and potential market leadership in bladder cancer treatment.
Analyst Views on CGON
Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 75.17 USD with a low forecast of 55.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 55.100
Low
55.00
Averages
75.17
High
108.00
Current: 55.100
Low
55.00
Averages
75.17
High
108.00
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
